With a background over 15 years in financial services & the Fintech accountancy sectors, Phil have worked for some of the largest and most innovative businesses in these industries, including Intuit, Natwest Banking Group, HSBC (as a consultant) and now Wolters Kluwer.
Phil is a business and strategy contributor for Elite Business Magazine online, a serial podcast host, judge for UK Business Tech awards 2021/22 & the Global Tech awards 2022 , a public speaker (having spoken at Elite Business Live x3, Accountex x3, QuickBooks Get Connected, Customer Engagement Transformation Conference and more) and guested on numerous industry podcasts (Accounting Influencers, Humanise The Numbers, Advance Track) and webinars including with industry bodies such as the ACCA.
During his previous role as Head of Customer Education, Phil built, designed and delivered the Capitalise education programme (both in person and self serve) working with over 1700 accountants in 3 years, from Top 25 through to leading niche and boutique firms across the UK and South Africa helping them implement funding as a service for their small business clients.
Dr. Hans-Heinrich Nickell has more than 20 years of experience in clinical development support for pharmaceutical companies, biotech, medical device and vaccine industries. He holds a degree in Pharmacy from the Philipps University in Marburg and a degree for Human Medicine from the Albert-Ludwigs University in Freiburg. After clinical work as a medical doctor at the University Clinic in Lübeck he started his career in 1995 in the pharmaceutical industry working for biotech companies. From 1999 he has worked in Business Development for major CROs with a focus on Medical Devices, CNS, Infectious Diseases, Immunotherapy, Vaccines and Oncology.
John has been working to help businesses adopt better working practices for over 15 years, having provided information and digital management consultancy to some of the world’s leading global brands. John believes that technology should work for us, and not distract us from what is important.
Matthew was appointed FNZ Group Proposition Director in 2022, responsible for developing the vision and roadmap behind FNZ’s overall proposition.
He joined FNZ in December 2012 as Head of Institutional Product before going on to lead the Proposition team in 2014. Matthew was appointed Chief Executive Officer, UK & SA in February 2019 where he successfully led the execution of many of FNZ’s largest and most complex client deliveries, managed a significant number of large customers and grew the business at record pace.
Prior to joining FNZ, Matthew spent 7 years at Cofunds where he held a number of roles across Operations, IT and eventually as Head of Product for the Cofunds Institutional Service.
Before this, Matthew’s career also included roles at Sumitomo Trust and Banking, Citibank and UBS where he held multiple roles across Operations, IT and Treasury.
Philippe is the Head of Switzerland for FNZ where he particularly works with Private Banks.
Philippe has 30 years of experience in the industry advising Private Banking clients and Private Banks.
Prior to FNZ, Philippe worked in the industry at UBS Wealth Management in various roles and as Partner in Strategy Consulting advising Wealth & Asset Managers on growth, digital strategies and their transformation plans. He worked with more than 50 Private Banks – global, regional or domestic leaders – on all continents and in both offshore and/or onshore markets – seeking to improve their competitive position and economics. Philippe also advised wealthy individuals on leaving a legacy.
Dr. William Jackson, PhD is a chemist who studied at Imperial College and MIT. Subsequently, he worked for 10 years in medicinal chemistry research followed by 10 years developing processes in the generic pharmaceutical industry. Since 2000 Dr. Jackson has been working in contract R&D for a variety of clients and, since 2017, with he has worked with Zanoprima Lifesciences, where he is now the Director of Development and Manufacturing.
Derek Yach is a global public health leader with deep experience based on years of work for WHO, leading corporations including PepsiCo, investment funds, academia (as Professor of Global Health at Yale), and not-for-profit organizations such as the Rockefeller and Smoke Free Foundations. His focus in these diverse settings has been to lead initiatives with impact on chronic diseases and their risks, and on mental health. Looking forward, he believes that governments, industry and investors need to give far greater focus to the health of adults as the pandemic recedes if we are to build more resilient and productive populations. He has focused on ways to implement harm reduction strategies within the context of substance abuse, tobacco control and food and nutrition policy. He has degrees in medicine and public health.
